Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence.
Esmée P HoefsmitFranziska VöllmyElisa A RozemanIrene L M ReijersJudith M VersluisLiesbeth HoekmanAlexander C J van AkkooiGeorgina V LongDirk SchadendorfReinhard DummerA F Maarten AltelaarChristian U BlankPublished in: Cancer research communications (2023)
LRG1 could serve as a potential target and as a biomarker to identify patients with high risk for disease recurrence, and consequently benefit from additional therapies and intensive follow-up.